321 related articles for article (PubMed ID: 2168285)
21. [Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line].
Aiba K; Funakoshi S; Mizunuma N; Dobashi N; Hirano A; Sano M; Kuraishi Y; Kamada M; Ohno N; Sugimoto Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1601-6. PubMed ID: 8060134
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
24. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
26. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
Tanizawa A; Pommier Y
Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
[TBL] [Abstract][Full Text] [Related]
28. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG
Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731
[TBL] [Abstract][Full Text] [Related]
29. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Voigt W; Vanhoefer U; Yin MB; Minderman H; Schmoll HJ; Rustum YM
Anticancer Res; 1997; 17(5A):3707-11. PubMed ID: 9413228
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
32. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Ogasawara H; Nishio K; Kanzawa F; Lee YS; Funayama Y; Ohira T; Kuraishi Y; Isogai Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):124-9. PubMed ID: 7737904
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Kanzawa F; Nishio K; Kubota N; Saijo N
Cancer Res; 1995 Jul; 55(13):2806-13. PubMed ID: 7796407
[TBL] [Abstract][Full Text] [Related]
34. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
36. Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
Chang JY; Guo X; Chen HX; Jiang Z; Fu Q; Wang HK; Bastow KF; Zhu XK; Guan J; Lee KH; Cheng YC
Biochem Pharmacol; 2000 Mar; 59(5):497-508. PubMed ID: 10660116
[TBL] [Abstract][Full Text] [Related]
37. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
Bence AK; Mattingly CA; Burke TG; Adams VR
Cancer Chemother Pharmacol; 2004 Oct; 54(4):354-60. PubMed ID: 15197485
[TBL] [Abstract][Full Text] [Related]
38. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
39. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
40. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
